<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506790</url>
  </required_header>
  <id_info>
    <org_study_id>MBC 2</org_study_id>
    <nct_id>NCT02506790</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer</brief_title>
  <official_title>Phase II Multicenter Randomized Study to Compare Neoadjuvant Toremifene With Melatonin or Metformin Versus Toremifene in the Therapy of Locally Advanced Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Petrov Research Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Petrov Research Institute of Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the addition melatonin and metformin to toremifene in the treatment of
      locally advanced breast cancer. Third of patients will receive toremifene, other third will
      receive combination of melatonin and toremifene and other patients will receive combination
      of metformin and toremifene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The management of locally advanced breast cancer is complicated issue. Neoadjuvant treatment
      is often needed to downstage locally advanced ER positive BC tumors prior to surgery.
      However, many patients do not achieved objective response on treatment. The ability of
      melatonin and metformin to decrease side effects of chemotherapy had been investigated,
      moreover, several studies confirm, that this drugs in combination with conventional anti -
      estrogen treatment may increase objective response. But, this data is still controversial. We
      hypothesizes that the combinations of melatonin and metformin with conventional anti -
      estrogen such as toremifene could be more effective than toremifene alone in terms of
      response rate.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 months after FPFV</time_frame>
    <description>Response will evaluate by RECIST criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathomorphological response</measure>
    <time_frame>4 months after FPFV</time_frame>
    <description>Pathomorphological response will assess after surgery by Miller and Payne Scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events incidence</measure>
    <time_frame>Until 30 days after last patient treatment visit</time_frame>
    <description>Incidence of AE classified using NCI Common Terminology Criteria for AE v4</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Toremifene and metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toremifene 60 mg daily with metformin 850 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toremifene and melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Toremifene 60 mg daily with melatonin 3 mg before sleep daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Toremifene</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Toremifene 60 mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <arm_group_label>Toremifene and metformin</arm_group_label>
    <other_name>siofor 850</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <arm_group_label>Toremifene and melatonin</arm_group_label>
    <other_name>melaxen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toremifene</intervention_name>
    <arm_group_label>Toremifene and metformin</arm_group_label>
    <arm_group_label>Toremifene and melatonin</arm_group_label>
    <arm_group_label>Toremifene</arm_group_label>
    <other_name>farestone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18.

          -  Obtained Inform Concent.

          -  Morphologically confirmed breast cancer stage IIB, IIIA, IIIB, IIIC ER positive.

          -  Eastern Collaborative Oncology Group Performance Status Scale 0-2.

          -  Expected survival &gt; 6 month.

          -  Adequate liver and bone marrow function.

        Exclusion Criteria:

          -  Systemic treatment for breast cancer.

          -  Stage IV disease.

          -  Evidence of liver and bone marrow clinically meaningful disfunction.

          -  Severe uncontrolled concomitant conditions and diseases.

          -  Pregnancy or lactation.

          -  Second malignancy.

          -  Diabetes mellitus requiring drug therapy.

          -  Any condition preventing study participation by investigators opinion.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir F Semiglazov, MD,PhD, DSc, Professor</last_name>
    <role>Study Director</role>
    <affiliation>N.N. Petrov Research Institute Of Oncology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tatiana Y Semiglazova, MD, PhD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>N.N. Petrov Research Institute Of Oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatiana Y Semiglazova, MD, PhD, DSc</last_name>
    <phone>+79219468072</phone>
    <email>tsemiglazova@mail.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>N.N. Petrov Research Institute of Oncology Clinical Diagnostic Department</name>
      <address>
        <city>Saint - Petersburg</city>
        <zip>191124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatiana Y Semiglazova, MD, PhD, DSc</last_name>
      <phone>+79219468072</phone>
      <email>tsemiglazova@mail.ru</email>
    </contact>
    <investigator>
      <last_name>Petr V Krivorotko, MD, PhD, DSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tatiana Y Semiglazova, MD, PhD, DSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>April 3, 2017</last_update_submitted>
  <last_update_submitted_qc>April 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Melatonin, metformin, toremifene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Toremifene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

